Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF -Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial. Paolo A. Ascierto , Mario Mandalà , Pier Francesso Ferrucci , Massimo Guidoboni , Piotr Rutkowski , Virginia Ferraresi , Ana Arance , Michele Guida , Evaristo Maiello , Helen Gogas , Erika Richtig , Maria Teresa Fierro , Celeste Lebbè , Hildur Helgadottir , Paola Queirolo , Francesco Spagnolo , Marco Tucci , Michele Del Vecchio , Maria Gonzales Cao , Alessandro Marco Minisini , Sabino De Placido , Miguel F. Sanmamed , Domenico Mallardo , Marcello Curvietto , Ignacio Melero , Giuseppe Palmieri , Antonio M. Grimaldi , Diana Giannarelli , Reinhard Dummer , Vanna Chiarion Sileni Journal of clinical oncology : official journal of the American Society of Clinical Oncology（2023）
摘要
Sequential immunotherapy and targeted therapy provide clinically meaningful survival benefits for patients with -mutant melanoma.
更多 查看译文
AI 理解论文
溯源树
样例
